Our Maybridge screening compounds and libraries have been at the forefront of innovative screening compound design for over 50 years, supporting the needs of drug discovery scientists in their pursuit of novel molecules of pharmaceutical interest.
The drug discovery process is long and expensive. Our aim is to shorten this process by producing high-quality, hit-like, lead-like, and drug-like compounds that generate valuable data from screening programs.
Accelerating drug discovery
The Maybridge screening collection consists of a highly diverse set of over 51,000 hit-like and lead-like molecules widely acknowledged as a critical tool in screening campaigns. These are individually designed compounds, produced by innovative synthetic techniques.
The core of the Maybridge building block collection, these pharmacophorically rich intermediates are specifically designed for medicinal chemistry, allowing logical SAR development and hit-to-lead optimization. Many will be of particular interest as “privileged structures,” while others bearing solubilizing moieties add to the pharmacokinetic profile of drug molecules.
Fragment screening is the method of choice in the quest for the rapid identification of new lead molecules in drug discovery. Select any combination from 30,000 chemical fragments to accelerate structure-based lead identification.
Rapid Equilibrium Dialysis (RED) device for plasma protein binding studies to quantify free "active" fraction of drugs in plasma.
Availability and stock quantities
Typically, about 95% of the compounds in our collection are available in >5 mg stock quantities and over 90% of the compounds are available in >50 mg stock quantities. A large proportion of our collection is available in gram quantities—this means we can ensure a very high level of re-supply of originally tested compounds. We provide most major brands of plates and vials, but are happy to use those supplied by customers on request.
Supply formats
In order to facilitate screening, selected compounds are available in two pre-plated formats and in vials with stock available for follow-up when required.
- 96-well plates with 1 μmol dry film
- 384-well microplates with 0.25 μmol dry film
96-well plates may be provided at mass ≥2 µmol or ≥0.5 mg as powder, dry films, or frozen DMSO solutions. 96- or 384-well plates may be provided at mass 0.1 µmol or 0.01 mg as dry films or frozen DMSO solutions. Compounds may also be ordered in vials at mass 2 µmol or 0.5 mg as powder or DMSO solutions.
Our Maybridge compounds team can provide most major brands of plates and vials, but we are happy to use those supplied by customers on request.
High-Throughput Screening (HTS) and Fragment-Based Drug Discovery (FBDD)
Learn why early-phase drug discovery should not be like looking for a needle in a haystack!
Resources
Maybridge library—Download any or all of the Maybridge library structure files.
For Research Use Only. Not for use in diagnostic procedures.